Dear Certified Prescriber:

Aegerion Pharmaceuticals Inc. (Aegerion) has made significant modifications to the REMS for JUXTAPID to help ensure that the benefits of treatment with JUXTAPID outweigh the risk of hepatotoxicity.

The modifications to the REMS will require all certified prescribers to be recertified in the JUXTAPID REMS Program by 2 July, 2017 by doing the following:

1. **Review:**
   - The JUXTAPID Prescribing Information (PI); and JUXTAPID REMS Program Fact Sheet (enclosed)

2. **Complete:**
   - The revised on-line JUXTAPID REMS Program Prescriber Training Module and Knowledge Assessment

3. **Agree:**
   - To counsel all patients on the JUXTAPID REMS Program using the JUXTAPID REMS Program Patient Guide and
   - To complete the JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form.

4. **Submit:**
   - The JUXTAPID REMS Program Prescriber Enrollment Form and the Certificate of Completion for the Prescriber Training Module and Knowledge Assessment to the JUXTAPID REMS Coordinating Center.

*** Prescribers who do not recertify in the JUXTAPID REMS Program by 2 July 2017 will be decertified and will be unable to prescribe JUXTAPID. ***
Complete details about the modified JUXTAPID REMS Program can be found at www.juxtapidREMSProgram.com. For more information, you may also contact the JUXTAPID REMS Program toll-free at 1-855-JUXTAPID (1-855-898-2743).

Sincerely,

Pamela Foulds, M.D.
Chief Medical Officer
Aegerion Pharmaceuticals, Inc.

Attachments:
JUXTAPID REMS Program Fact Sheet
JUXTAPID Prescribing Information